Trends in innovation for downstream process intensification, product yield, single use closed systems, and gentle ATMP bioprocessing: a KOL panel discussing 2024 insights in gene therapy manufacturing

Cell & Gene Therapy Insights 2024; 10(3), 469–478

DOI: 10.18609/cgti.2024.060

Published: 7 May
Innovator Insight
Rachel Legmann, Andrew D Tustian

Rachel Legmann, Senior Director of Technology, Gene Therapy, Repligen, and Andrew D Tustian, Senior Director of Viral Vector Process Development Group, Regeneron, discuss downstream AAV processes while exploring the trends in outsourcing versus in-house manufacturing and evolving supply chain solutions.